How has Corvus Pharmaceuticals's other commercial liabilities changed year-over-year?

Corvus Pharmaceuticals's other commercial liabilities increased by 80.4% year-over-year, from $3.87M to $6.99M.

What is the long-term trend for Corvus Pharmaceuticals's other commercial liabilities?

Over 2 years (2023 to 2025), Corvus Pharmaceuticals's other commercial liabilities has grown at a 27.8% compound annual growth rate (CAGR), from $3.97M to $6.49M.

Corvus Pharmaceuticals CRVS Other Commercial Liabilities

Other Commercial Liabilities at other companies

Aclaris TherapeuticsACRS

——

Cullinan Therapeutics, Inc.CGEM

——

Nektar TherapeuticsNKTR

——

Vor BiopharmaVOR

——

Kymera TherapeuticsKYMR

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Operating income-$14.9M-49.9%

Net income-$13.7M-190%

EPS (diluted)-$0.15-15.4%

Balance sheet

See full

Cash & equivalents$40.1M+702%

Total debt$834.0K-27.7%

Total equity$240.7M+388%

Total assets$253.2M+326%

Cash flow

See full

Operating cash flow-$10.4M-25.5%

CapEx$91.0K+153%

Free cash flow-$10.5M-26.1%

Valuation

See full

Market cap$1.1B+259%

Enterprise value$1.06B+251%

Returns & leverage

See full

Return on equity-30.5%-12.5pp

Debt / equity0×0.0×

Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corvus Pharmaceuticals's other commercial liabilities?: Corvus Pharmaceuticals (CRVS) reported other commercial liabilities of $6.99M in Q1 2026.
How has Corvus Pharmaceuticals's other commercial liabilities changed year-over-year?: Corvus Pharmaceuticals's other commercial liabilities increased by 80.4% year-over-year, from $3.87M to $6.99M.
What is the long-term trend for Corvus Pharmaceuticals's other commercial liabilities?: Over 2 years (2023 to 2025), Corvus Pharmaceuticals's other commercial liabilities has grown at a 27.8% compound annual growth rate (CAGR), from $3.97M to $6.49M.